Brief: Clover Biopharmaceuticals Expects Commercial Launch For SCB-2019 In China To Begin In Q1 2023
16/01/2023 01:05
Jan 16 (Reuters) - Clover Biopharmaceuticals Ltd
2197.HK :
* COMMERCIAL LAUNCH FOR SCB-2019 IN CHINA IS EXPECTED TO
BEGIN IN
Q1 OF 2023
Source text for Eikon: ID:nHKS15QQcw
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune